Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt No Debt
CRMD's Cash to Debt is ranked higher than
90% of the 1233 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. CRMD: No Debt )
CRMD' s 10-Year Cash to Debt Range
Min: 0.11   Max: No Debt
Current: No Debt

Equity to Asset 0.82
CRMD's Equity to Asset is ranked higher than
84% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CRMD: 0.82 )
CRMD' s 10-Year Equity to Asset Range
Min: -1.36   Max: 0.82
Current: 0.82

-1.36
0.82
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -7785.85
CRMD's Operating margin (%) is ranked higher than
51% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: -80.68 vs. CRMD: -7785.85 )
CRMD' s 10-Year Operating margin (%) Range
Min: -245750   Max: -14155.56
Current: -7785.85

-245750
-14155.56
Net-margin (%) -20447.17
CRMD's Net-margin (%) is ranked lower than
52% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. CRMD: -20447.17 )
CRMD' s 10-Year Net-margin (%) Range
Min: -456650   Max: -35442.59
Current: -20447.17

-456650
-35442.59
ROA (%) -375.41
CRMD's ROA (%) is ranked lower than
52% of the 1231 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. CRMD: -375.41 )
CRMD' s 10-Year ROA (%) Range
Min: -1289.69   Max: -116.99
Current: -375.41

-1289.69
-116.99
ROC (Joel Greenblatt) (%) -23715.52
CRMD's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 1204 Companies
in the Global Biotechnology industry.

( Industry Median: -480.34 vs. CRMD: -23715.52 )
CRMD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -77336.36   Max: -23975.61
Current: -23715.52

-77336.36
-23975.61
EBITDA Growth (%) 18.60
CRMD's EBITDA Growth (%) is ranked lower than
114% of the 705 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. CRMD: 18.60 )
CRMD' s 10-Year EBITDA Growth (%) Range
Min: -66.7   Max: 18.6
Current: 18.6

-66.7
18.6
EPS Growth (%) 22.60
CRMD's EPS Growth (%) is ranked lower than
111% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. CRMD: 22.60 )
CRMD' s 10-Year EPS Growth (%) Range
Min: -68.4   Max: 22.6
Current: 22.6

-68.4
22.6
» CRMD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

CRMD Guru Trades in Q4 2013

Paul Singer 781,440 sh (unchged)
» More
Q1 2014

CRMD Guru Trades in Q1 2014

Paul Singer 781,440 sh (unchged)
» More
Q2 2014

CRMD Guru Trades in Q2 2014

Paul Singer 781,440 sh (unchged)
» More
Q3 2014

CRMD Guru Trades in Q3 2014

Paul Singer 781,440 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CRMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.30
CRMD's P/B is ranked higher than
71% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 5.68 vs. CRMD: 6.30 )
CRMD' s 10-Year P/B Range
Min: 0   Max: 6.2
Current: 6.3

0
6.2
P/S 288.30
CRMD's P/S is ranked lower than
54% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 32.77 vs. CRMD: 288.30 )
CRMD' s 10-Year P/S Range
Min: 0   Max: 10793.6
Current: 288.3

0
10793.6
EV-to-EBIT -3.62
CRMD's EV-to-EBIT is ranked higher than
56% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CRMD: -3.62 )
CRMD' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -3.62

Current Ratio 5.53
CRMD's Current Ratio is ranked higher than
76% of the 1225 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. CRMD: 5.53 )
CRMD' s 10-Year Current Ratio Range
Min: 0.1   Max: 10.33
Current: 5.53

0.1
10.33
Quick Ratio 4.98
CRMD's Quick Ratio is ranked higher than
75% of the 1225 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. CRMD: 4.98 )
CRMD' s 10-Year Quick Ratio Range
Min: 0.1   Max: 10.33
Current: 4.98

0.1
10.33

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.00
CRMD's Price/Net Cash is ranked higher than
86% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 105.66 vs. CRMD: 7.00 )
CRMD' s 10-Year Price/Net Cash Range
Min: 2.11   Max: 23.25
Current: 7

2.11
23.25
Price/Net Current Asset Value 6.39
CRMD's Price/Net Current Asset Value is ranked higher than
86% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 37.29 vs. CRMD: 6.39 )
CRMD' s 10-Year Price/Net Current Asset Value Range
Min: 2.11   Max: 23.25
Current: 6.39

2.11
23.25
Price/Tangible Book 5.88
CRMD's Price/Tangible Book is ranked higher than
78% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. CRMD: 5.88 )
CRMD' s 10-Year Price/Tangible Book Range
Min: 2.05   Max: 15.17
Current: 5.88

2.05
15.17
Earnings Yield (Greenblatt) -25.80
CRMD's Earnings Yield (Greenblatt) is ranked higher than
59% of the 1141 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. CRMD: -25.80 )
CRMD' s 10-Year Earnings Yield (Greenblatt) Range
Min: -28.9   Max: 0
Current: -25.8

-28.9
0
Forward Rate of Return (Yacktman) -10.51
CRMD's Forward Rate of Return (Yacktman) is ranked higher than
57% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -6.43 vs. CRMD: -10.51 )
CRMD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -10.51

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Cormedix, Inc. was organized as a Delaware corporation on July 28, 2006 under the name Picton Holding Company, Inc. and changed it to CorMedix Inc. on January 18, 2007. The Company develops and seeks to commercialize products for the treatment of cardiac, renal and infectious diseases. Its principal product under development includes CRMD003, an antimicrobial/anticoagulant solution applied in the prevention of catheter related bloodstream infections and maintenance of catheter patency in central venous catheters used for vascular access in hemodialysis patients. Its products also include CRMD004, a pressure sensitive gel that is in pre-clinical Phase.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK